CORDIS
EU research results

CORDIS

English EN
Targets and biomarkers for antiepileptogenesis

Targets and biomarkers for antiepileptogenesis

Objective

Epilepsy is a devastating condition affecting over 50 million people worldwide. This multidisciplinary project is focused on the process leading to epilepsy, epileptogenesis, in adults. Our main hypothesis is that there are combinations of various causes, acting in parallel and/or in succession, that lead to epileptogenesis and development of seizures. Our central premise and vision is that a combinatorial approach is necessary to identify appropriate biomarkers and develop effective antiepileptogenic therapeutics. The project will focus on identifying novel biomarkers and their combinations for epileptogenesis after potentially epileptogenic brain insults in clinically relevant animal models, such as traumatic brain injury (TBI) and status epilepticus (SE); explore multiple basic mechanisms of epileptogenesis and their mutual interactions related to cell degeneration, circuit reorganization, inflammatory processes, free radical formation, altered neurogenesis, BBB dysfunction, genetic and epigenetic alterations; and translating these findings towards the clinic by validating biomarkers identified from animal models in human post TBI brain tissue and blood samples, post-mortem brain tissue in individuals that died soon after SE, and human brain and blood samples from chronic epilepsy cases. The project will identify novel combinatorial biomarkers and novel disease-modifying combinatorial treatment strategies for epileptogenesis, create an Epilepsy Preclinical Biobank, and validate translational potential of results from animal models in human tissue. To adequately address the proposed goals, the project will develop technological breakthroughs, such as completely novel chemogenetic approaches, novel MRI techniques, novel multimodal organic recording devices for simultaneous recordings of EEG / cellular unit activity and biochemical measurements, novel bioluminescence for in vivo promoter activity analysis, and novel systems biology approaches.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

LUNDS UNIVERSITET

Address

Paradisgatan 5c
22100 Lund

Sweden

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 2 077 141

Administrative Contact

Merab Kokaia (Prof.)

Participants (19)

Sort alphabetically

Sort by EU Contribution

Expand all

LIFE AND BRAIN GMBH

Germany

EU Contribution

€ 500 000

MICROVITAE TECHNOLOGIES SAS

France

EU Contribution

€ 495 300

ITA-SUOMEN YLIOPISTO

Finland

EU Contribution

€ 1 045 000

ISTITUTO DI RICERCHE FARMACOLOGICHE MARIO NEGRI

Italy

EU Contribution

€ 687 500

STIFTUNG TIERAERZTLICHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 523 620

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 1 481 344

UNIVERSITAETSKLINIKUM BONN

Germany

EU Contribution

€ 642 000

INSTYTUT BIOLOGII DOSWIADCZALNEJ IM. M. NENCKIEGO POLSKIEJ AKADEMII NAUK

Poland

EU Contribution

€ 352 000

UNIVERSITE D'AIX MARSEILLE

France

EU Contribution

€ 530 540

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

United Kingdom

EU Contribution

€ 672 599

UNIVERSITA DEGLI STUDI DI FERRARA

Italy

EU Contribution

€ 475 000

Academisch Medisch Centrum bij de Universiteit van Amsterdam

Netherlands

EU Contribution

€ 645 480

BEN-GURION UNIVERSITY OF THE NEGEV

Israel

EU Contribution

€ 399 980

GABO:MI GESELLSCHAFT FUR ABLAUFORGANISATION:MILLIARIUM MBH & CO KG

Germany

EU Contribution

€ 130 525

BIOVIRON SARL

France

EU Contribution

€ 399 214

MEDIZINISCHE HOCHSCHULE HANNOVER

Germany

EU Contribution

€ 406 655

TO-BBB TECHNOLOGIES BV

Netherlands

EU Contribution

€ 133 311

NANOMERICS LTD

United Kingdom

EU Contribution

€ 46 800

ARTTIC

France

EU Contribution

€ 355 966

Project information

Grant agreement ID: 602102

Status

Closed project

  • Start date

    1 November 2013

  • End date

    31 October 2018

Funded under:

FP7-HEALTH

  • Overall budget:

    € 15 775 099,01

  • EU contribution

    € 11 999 975

Coordinated by:

LUNDS UNIVERSITET

Sweden